Clinical Trials Logo

Recurrent Prostate Cancer clinical trials

View clinical trials related to Recurrent Prostate Cancer.

Filter by:

NCT ID: NCT03496805 Not yet recruiting - Clinical trials for Recurrent Prostate Cancer

Effects of Muscadine Grape Extract in Men With Biochemically Recurrent Prostate Cancer on Androgen Deprivation Therapy

Start date: June 2018
Phase: Phase 2
Study type: Interventional

It is estimated that one-third of the more than 7 million deaths from cancer worldwide are attributable to potentially modifiable risk factors, with 374,000 deaths preventable through diet modification alone. Diet supplementation for the prevention or treatment of cancer is attractive, as implementation is relatively easy, even in populations with reduced incomes and resources. Grape extracts or active components isolated from grapes have received attention as chemopreventive or therapeutic agents based upon their anti-proliferative, anti-inflammatory, and anti-oxidant properties. Evidence from preclinical trials also suggests that muscadine grape products may decrease systemic inflammation. This study builds upon promising preclinical and clinical evidence to determine if the addition muscadine grape extract (MGE) to androgen deprivation therapy (ADT) improves symptoms in men with prostate cancer.

NCT ID: NCT03495427 Not yet recruiting - Prostate Cancer Clinical Trials

PSMA-PET Imaging for Detecting Early Metastatic Prostate Cancer in Men w/ High Decipher Test Scores

Start date: June 2018
Phase: Phase 2/Phase 3
Study type: Interventional

This study will enroll 60 patients previously enrolled to MCC#18523, "A Validation Study on the Impact of Decipher® Testing on Treatment Recommendations in African-American and Non-African American Men with Prostate Cancer: (VANDAAM)" that had high risk Decipher test results (Decipher score >0.45). Patients with a high genomic classifier (GC) score at diagnosis will be approached for formal consenting for PSMA-PET imaging at 2 years post treatment.

NCT ID: NCT03246802 Recruiting - Clinical trials for Recurrent Prostate Cancer

Partial Prostate Salvage High Dose Rate Brachytherapy

Start date: January 1, 2018
Phase: N/A
Study type: Interventional

A dose-response relationship for radiation in the management of prostate cancer is well established. Local recurrence of prostate cancer after external beam radiotherapy occurs in at least 40% of patients treated because of inability to deliver sufficient dose through external beam techniques. These patients respond well to re-irradiation using brachytherapy with about 50% of selected patients remaining free of recurrence 5 years after salvage. Advanced imaging using multiparametric Magnetic Resonance Imaging (mpMRI) allows identification of the site of recurrence, permitting partial prostate salvage brachytherapy. There is extensive literature on Low Dose Rate salvage brachytherapy but less on High Dose Rate.

NCT ID: NCT03067051 Recruiting - Clinical trials for Recurrent Prostate Cancer

Clinical Study to Assess the Safety and Adequacy of Effectiveness of the SpectraCure P18 System

Start date: March 21, 2017
Phase: Phase 1
Study type: Interventional

The rationale for the study is to obtain safety data as well as to establish dose parameters for the SpectraCure P18 System with IDOSE®, with verteporfin for injection (VFI) as photosensitizer for the treatment of recurrent prostate cancer.

NCT ID: NCT02531672 Available - Prostate Cancer Clinical Trials

Detecting Recurrent Prostate Cancer With 11C-choline Positron Emission Tomography

Start date: n/a
Phase: N/A
Study type: Expanded Access

The purpose of this study is to use a new imaging drug called 11C-choline that is used with a PET/CT scan to see prostate cancer when it cannot be seen well on other scans, such as bone scans, CT or MRI.

NCT ID: NCT02452307 Active, not recruiting - Clinical trials for Recurrent Prostate Cancer

Peptide-specific Vaccination in HLA-A*02 Positive Patients With Biochemical Recurrence After Radical Prostatectomy

Start date: April 2004
Phase: Phase 1/Phase 2
Study type: Interventional

The study evaluates the prostate-specific antigen (PSA) response in HLA-A*02 positive patients with biochemical recurrence after radical prostatectomy treated with a prostate-specific peptide vaccine in combination with different immune-adjuvants.

NCT ID: NCT02278185 Recruiting - Clinical trials for Adenocarcinoma of the Prostate

Enzalutamide Versus Standard Androgen Deprivation Therapy for the Treatment Hormone Sensitive Prostate Cancer

Start date: November 11, 2015
Phase: Phase 2
Study type: Interventional

This randomized phase II trial compares enzalutamide with standard androgen deprivation therapy in reducing incidence of metabolic syndrome in patients with prostate cancer that has spread to other places in the body. Metabolic syndrome is defined as changes in cholesterol, blood pressure, circulating sugar levels, and body weight. Previous studies have shown that patients with prostate cancer, who have been treated with standard medical therapy that lowers testosterone levels, have an increased risk of these changes. Hormone therapy using enzalutamide may fight prostate cancer by blocking the use of testosterone by the tumor cells instead of lowering testosterone levels. It is not yet known whether prostate cancer patients who receive enzalutamide will have reduced incidence of metabolic syndrome than patients who receive standard androgen deprivation therapy.

NCT ID: NCT02250014 Active, not recruiting - Clinical trials for Recurrent Prostate Cancer

The Immuno-Response to Primary Cryotherapy for the Treatment of Prostate Cancer

Start date: October 5, 2015
Phase: Phase 1
Study type: Interventional

This randomized pilot phase I trial studies how well sargramostim after cryotherapy works in treating patients with prostate cancer. Biological therapies, such as sargramostim, use substances made from living organisms that may stimulate the immune system in different ways and stop tumor cells from growing. Cryosurgery, also known as cryotherapy, kills tumor cells by freezing them. Giving sargramostim after cryotherapy may work better in treating prostate cancer.

NCT ID: NCT02217709 Recruiting - Clinical trials for Adenocarcinoma of the Prostate

Phenelzine Sulfate in Treating Patients With Non-metastatic Recurrent Prostate Cancer

Start date: September 8, 2014
Phase: Phase 2
Study type: Interventional

This phase II trial studies phenelzine sulfate in treating patients with prostate cancer that has not spread to other parts of the body and has come back. Phenelzine sulfate is a type of antidepressant that works by decreasing the amount of a protein called monoamine oxidase (MAO). MAO drugs may have an anticancer effect in prostate cancer.

NCT ID: NCT02184533 Recruiting - Multiple Myeloma Clinical Trials

Sodium Selenite and Radiation Therapy in Treating Patients With Metastatic Cancer

Start date: July 2014
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the maximum-tolerated dose (MTD) of sodium selenite when administered in combination with radiation therapy to subjects with metastatic cancer based on safety and tolerability.